KleenAir Systems Inc. Receives Mayor's Emission Strategy For London Taxis
IRVINE, Calif.--Sept. 10, 2004--KleenAir Systems Inc. (OTCBB:KAIR) announced today that the company has received a draft of the Emission Strategy for London Taxis published in support of the Mayor's Air Quality Strategy. The letter indicates implementation plans for the upgrade of London Taxis to meet Euro 3 standards by 2007, starting in 2005.The letter stated that: "As of 1st April 2005 all taxis in service that are Pre-Euro emissions standard, will be required to have Public Carriage Office/Energy Savings Trust approved emissions reduction equipment fitted or a Public Carriage Office/Energy Savings Trust approved conversion to run on alternative fuels as a requirement of licensing."
KleenAir's NOxMaster(TM) NOx Reduction System and Diesel Particulate Filter (SCRF) has been on the EST CleanUp register since December 2002, along with LPG, the preferred alternative fuel solution. "I believe that initial capital costs and installation requirements will give KleenAir a significant advantage in meeting the taxi upgrade program and will be the product of choice," stated Lionel Simons, president of KleenAir Systems Inc.
As of April 1, 2006, Euro 1 taxis will have to meet Euro 3 standards, and as of April 1, 2007, Euro 2 taxis will have to meet the Euro 3 standards. The total number of vehicles impacted are estimated at 17,500.
KleenAir Systems Inc. recently announced that their U.K. affiliate recently signed a contract for a pre-IPO equity of $2.25 million with Hoodless Brennan, a London corporate broker and major fund-raiser active on the Alternative Investment Market (AIM).
About KleenAir
KleenAir is at the cutting edge of automotive emission reduction technology including Selective Catalytic Reduction (SCR), Diesel Particulate Filters, Diesel Oxidizing Catalysts and advanced catalytic technology that significantly reduces nitrogen oxides, carbon monoxide, hydrocarbon and particulates. These pollutants have been shown to be a major contributor to heart and lung disease.